SML2571

CPHPC

≥98% (HPLC)

• 別名: (2′R)-Adipoyldi-D-proline, (R)-1-[6-[(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl-]pyrrolidine-2-carboxylic acid, 1,1′-(1,6-Dioxo-1,6-hexanediyl)bis[D-proline], GSK 2315698, GSK-2315698, GSK2315698, Miridesap, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid, Ro 63-8695, Ro-63-8695
• 実験式（ヒル表記法）: C₁₆H₂₄N₂O₆
• CAS番号: 224624-80-0
• 分子量: 340.37
• MDL番号: MFCD09970762
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear
• 保管温度: −20°C
• SMILES記法: N2([C@H](CCC2)C(=O)O)C(=O)CCCCC(=O)N1[C@H](CCC1)C(=O)O
• InChI: 1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1
• InChI Key: HZLAWYIBLZNRFZ-VXGBXAGGSA-N

詳細

生物化学的／生理学的作用

CPHPC (Miridesap; Ro 63-8695) is an orally active serum amyloid P (SAP) blocker that targets the ligand-binding site on the SAP planar binding (B) face with each of its two D-proline moieties (up to two SAP per CPHPC), being able to crosslink and dimerize two SAP pentamers to form B face-to-B face decamers. CPHPC potently inhibits SAP binding to amyloid fibrils in vitro (IC50 = 0.9 μM using AD Aβ amyloid fibrils) and exhibits in vivo efficacy toward liver & circulating SAP clearance as well as SAP removal from tissue amyloid deposits (1-5 mg/mL in drinking water; human SAP transgenic mice).

Serum amyloid P (SAP) blocker that inhibits SAP binding to amyloid fibrils, clears circulating SAP and removes SAP from tissue amyloid deposits in vivo.

安全性情報

• ピクトグラム: GHS07
• シグナルワード: Warning
• 危険有害性情報: H302
• 注意書き: P264 - P270 - P301 + P312 - P501
• 危険有害性の分類: Acute Tox. 4 Oral
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable